PFEPfizerSigning up patients
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 492 (planned)
- Started
- Feb 8, 2024
- Main results expected
- Aug 30, 2026
- Fully finished
- Dec 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival per International Myeloma Working Group criteria
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06152575 · record last updated 2026-08-24 · checked 2026-11-09 15:36 UTC